BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 2674460)

  • 1. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
    J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
    Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
    Piccart MJ; Nogaret JM; Marcelis L; Longrée H; Ries F; Kains JP; Gobert P; Domange AM; Sculier JP; Gompel C
    J Natl Cancer Inst; 1990 Apr; 82(8):703-7. PubMed ID: 2181152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma.
    Edmonson JH; McCormack GW; Krook JE; Long HJ; Jefferies JA; Richardson RL
    Cancer Treat Rep; 1987 Feb; 71(2):199-200. PubMed ID: 3542210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin.
    Edmonson JH; Hartmann LC; Long HJ; Colon-Otero G; Fitch TR; Jefferies JA; Braich TA; Maples WJ
    Cancer; 1992 Nov; 70(10):2529-39. PubMed ID: 1423182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
    Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
    J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
    Alberts DS; Green S; Hannigan EV; O'Toole R; Stock-Novack D; Anderson P; Surwit EA; Malvlya VK; Nahhas WA; Jolles CJ
    J Clin Oncol; 1992 May; 10(5):706-17. PubMed ID: 1569443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
    Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.
    Evans BD; Raju KS; Calvert AH; Harland SJ; Wiltshaw E
    Cancer Treat Rep; 1983 Nov; 67(11):997-1000. PubMed ID: 6315233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.
    Bertelsen K; Bastholt L
    Gynecol Oncol; 1992 Jan; 44(1):79-82. PubMed ID: 1730430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
    Perez RP; Perez KM; Handel LM; Hamilton TC
    Cancer Chemother Pharmacol; 1992; 29(6):430-4. PubMed ID: 1568285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New regimens for the treatment of gynecologic cancers].
    Sugiyama T; Ushijima K; Kamura T
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):375-81. PubMed ID: 10740630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer.
    Gallagher CJ; Wiltshaw E; Coleman RE; Harper PG
    Cancer Chemother Pharmacol; 1989; 24(1):54-7. PubMed ID: 2655961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
    Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
    J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase I clinical study of combined cisplatin and carboplatin therapy in lung cancer].
    Hayasaka S; Yoshinaga T; Kinuwaki E; Kiyama T; Fujino N
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2011-6. PubMed ID: 1417008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.